Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II open-label study of HBW-012462 in KRAS-mutant advanced or metastatic solid tumors
CTR20254397Phase 2Active
- Sponsor
- Hyperway Pharmaceutical
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HBW-012462 in Nonhematologic neoplasms, sponsored by Hyperway Pharmaceutical. Started Nov 2025; status: active.
02
Drugs
HBW-012462
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20254397.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254397.